Yang Sun

Yang Sun

Auto-generated profile, based on publicly available information

Yang Sun

Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Haiyuncang Lane, Dongcheng District, Beijing, 100700, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
RZRui Zheng
Rui Zheng
Liyuan TaoLiyuan Tao
Liyuan Tao
JKJoey S.W. Kwong
Joey S.W. Kwong
CZChangming Zhong
Changming Zhong
CLChengyu Li
Chengyu Li
HSHongcai Shang
Hongcai Shang

25 February 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
RZRui Zheng
Rui Zheng
YSYang Sun
Yang Sun
XZXiaoyu Zhang
Xiaoyu Zhang
CZChen Zhao
Chen Zhao
PWPengqian Pengqian Wang
Pengqian Pengqian Wang
HSHongcai Shang
Hongcai Shang

8 January 2020 in Trials
Verified
Journal Article
Open access
PDF file
OIon behalf of the DIRECTION investigators
on behalf of the DIRECTION investigators
XZXiaoyu Zhang
Xiaoyu Zhang
GTGui-Hua Tian
Gui-Hua Tian
ZSZhaofeng Shi
Zhaofeng Shi
YSYang Sun
Yang Sun
HSHongcai Shang
Hongcai Shang
Background: No treatment has convincingly been proven to be beneficial for microvascular obstruction (MVO) in patients with ST-elevation myocardial infarction (STEMI). Several studies have described the effects of Danhong Injection. However, evidence of a rigorously designed verification study is still lacking, and the intervention timing of Danhong Injection is uncertain. Methods: The DIRECTION study is a multicenter, prospective, randomized, evaluator-blind study. A total of 336 patients with STEMI receiving percutaneous coronary intervention (PCI) will be randomly assigned to conventional treatment, the preoperative Danhong Injection, or the postoperative Danhong Injection. The primary outcome is rate of ST-segment resolution (STR) ≥ 70% at 90 min after PCI. The secondary outcomes are the degree of STR, Thrombolysis in Myocardial Infarction (TIMI) flow grade, TIMI myocardial perfusion grade, left ventricular ejection fraction, N-terminal prohormone brain natriuretic peptide, high-sensitivity C-reactive protein, and infarct size expressed as area under the curve for cardiac troponin I (cTnI) and for creatine kinase MB. The major adverse cardiovascular events and hospital readmission events will be recorded. Health quality will be assessed with the 12-item Short Form Health Survey. The safety outcomes include bleeding events, adverse events, and abnormal changes in routine blood tests. Psychological status and dietary patterns will be evaluated using Hamilton Depression Rating Scale and Food Frequency Questionnaire as the relevant indicators. Discussion: This trial will evaluate the efficacy and safety of Danhong Injection, as well as its optimal timing of intervention to prevent MVO in patients with STEMI. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900021440. Registered on February 21, 2019.